PeppiLibrary

Metabolic

Pemvidutide peptide reference

GLP-1/glucagon dual agonist. Targets both obesity and MASH simultaneously.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing Pemvidutide notes
Default dose label1.2 mg
Preferred routeSubQ
Frequency label1× weekly
Storage window28 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Phase 2 data; Phase 3 not yet — not approved

Investigational

Route map

How records are usually labeled

1 SubQ

Rotate weekly between sites.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; do not freeze.
After mixRefrigerate 2–8 °C, use within 28 days.
Use-by cue28 days after mixing
Mixed vial window28 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 5 mg vial
Dose 1.2 mg
Route SubQ
Review 28d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Pemvidutide. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Pemvidutide is a synthetic GLP-1/glucagon dual receptor agonist developed by Altimmune. It is unique in actively pursuing both obesity (MOMENTUM Phase 2) and metabolic dysfunction-associated steatohepatitis (MASH; IMPACT Phase 2) as primary indications. The glucagon arm is intended to drive direct hepatic fat reduction, addressing the liver-disease component that semaglutide and tirzepatide partially miss.

Also known as: ALT-801.

Obesity research (Phase 2 MOMENTUM)MASH / NAFLD research (Phase 2 IMPACT)Cardiometabolic risk reduction

Mechanism and timing snapshot

Dual agonist of GLP-1 and glucagon receptors with balanced potency. Glucagon arm drives hepatic lipolysis specifically — designed to reduce intrahepatic triglyceride.

Onset labelNot listed
Catalog onset field, when available.
Half-life label144 hr
~6–7 days; weekly dosing
Duration label168 hr
Catalog duration field, when available.
subQ High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose1.2 mg
Catalog dose range1.2 mg - 2.4 mg
Default routeSubQ
Frequency label1× weekly
Best time labelSame day each week.
Food noteNone for the injectable form.

Catalog protocol note

Trial dosing: 1.2 mg or 2.4 mg weekly. Slower titration than semaglutide reported for tolerability.

Routes and site notes

Available route labelsSubQ
Preferred route labelSubQ
Common site labelsAbdomen, Thigh
Site rotation noteRotate weekly between sites.

Chemistry

SequenceModified GLP-1/glucagon hybrid with C18 fatty acid; ~29 amino acids
Amino acids29
Molecular formulaNot listed
Molecular weight4400 Da

Vial, reconstitution, and storage

Supply formLyophilized powder (compounded only — no commercial form yet)
Typical vial size5 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration noteCompounded 5 mg in 2 mL → 0.48 mL = 1.2 mg dose.
Before reconstitutionRefrigerate 2–8 °C; do not freeze.
After reconstitutionRefrigerate 2–8 °C, use within 28 days.
Reconstituted shelf life28 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Nausea (~25%)
  • GI symptoms
  • Decreased appetite
  • Injection-site reactions
  • Pancreatitis
  • Mild heart rate elevation

Contraindications and warnings

  • Personal/family history of medullary thyroid carcinoma
  • MEN 2 syndrome
  • Pregnancy
  • Investigational — not yet FDA-approved.

Other considerations

  • Differentiator vs semaglutide is the glucagon-driven hepatic fat reduction.
  • MASH-focused indication is a real potential unmet-need market.
  • Available only via compounding pharmacies until approval.

Evidence and regulatory context

Evidence levelPhase 2 data; Phase 3 not yet — not approved
FDA approvedNo
Regulatory statusInvestigational
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withNot listed
Avoid combining noteOther GLP-1 or glucagon agonists
Typical cycle labelongoing
Typical break labelNot typically cycled
Cycle guidanceUsed continuously per trial protocols.

Tracking tips

  • Earlier in development than survodutide — Phase 2 vs Phase 3.
  • Compelling if liver fat is part of your concern alongside body weight.
  • Compounded supply quality varies; verify your source.

References

Track it in Peppi

Keep Pemvidutide records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Pemvidutide?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Pemvidutide?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Pemvidutide records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026